NEW YORK, July 15 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, was featured on CBS2 News, New York City's local CBS station, on Monday evening July 13 and Tuesday morning July 14, 2009.
The segment "Go! New York" focused on the work of Dr. Christopher Centeno, a NeoStem consultant in stem cell therapies for orthopedics, and featured the success of his innovative process that rapidly grows a patient's own adult stem cells to treat a variety of musculoskeletal diseases. Interviews with Dr. Centeno at the Centeno-Schultz Clinic near Denver, Colorado, and Dr. Robin Smith, CEO of NeoStem, were included.
Dr. Max Gomez, CBS2's medical expert, stated that autologous adult stem cells "have become the cutting edge way to treat osteoarthritis of the knee, hip, and ankle and even back pain." He noted, "The promise appears to be so great that more than 1,000 clinical trials are testing stem cell therapies" for various conditions and "showing promising results for heart failure, diabetes, lupus and even macular degeneration." He added, "That's why a company called NeoStem has begun banking people's own adult stem cells -- now, before you need them."
To see the video of the segment, please go to: http://wcbstv.com/video/?id=130168@wcbs.dayport.com
NeoStem holds an exclusive royalty-bearing, perpetual and irrevocable license to use this technology of Dr. Centeno and Regenerative Sciences, Inc. in the People's Republic of China (PRC) -- as announced on May 11, 2009. The first such use is anticipated to be at the Wendeng Orthopedic Hospital in Shandong, one of the leading specialist orthopedic hospitals in China. NeoStem, through its affiliate in China, is in the process of implementing a plan to offer these orthopedic treatments in China through an initial network of hospitals, of which Wendeng Hospital is the first. Dr. Centeno has been engaged to provide consulting services, including selecting a suitable PRC partner hospital and assessing and training medical staff in relation to the provision of stem cell therapies for orthopedics.
Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are very excited to be working with Dr. Centeno to bring this therapy to China and believe that with Neostem's technology we can make the therapy less invasive and in the future there will not be the need as there is today for stem cell expansion." As Dr. Gomez pointed out, adult stem cell therapies are being successfully applied in an increasing number of medical areas.
